Stock Watch: All Roads Lead Back To Pricing In Biogen And J&J’s Third-Quarter Earnings
A Mixed Start To The Third-Quarter Earnings Season Brought Some Unwelcome Recurring Themes
Johnson & Johnson’s divisional recoveries were in contrast to the declines of Biogen’s franchises but both companies had a competitive pressure and a drug pricing issue.
